Postinfarction left ventricular remodeling: a pathophysiological and therapeutic review.
Over the last 50 years, studies investigating the pathogenesis of left ventricular dysfunction have resulted in many potential therapeutic targets being identified and novel classes of drugs designed to treat this condition. Despite this, the long-term prognosis of patients with clinical heart failure remains poor with mortality rates equivalent to many terminal malignancies. This article reviews our present understanding of the pathophysiology of post-infarction left ventricular dysfunction and provides a rationale for current drug usage, drugs undergoing clinical trials and compounds still under pre-clinical development. In addition, the complexities involved in deciphering intra-cellular signalling pathways mediating ventricular hypertrophy which may form the basis of future treatments are also discussed.
Yousef
Z R
ZR
Department of Cardiology, Rayne Institute, Kings College London, UK.
Redwood
S R
SR
Marber
M S
MS
D000818:Animals; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*; D020257:Ventricular Remodeling / Q000502:physiology*